Cargando…

Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays

Cystic fibrosis (CF) is a genetic disease affecting the lungs and pancreas and causing progressive damage. CF is caused by mutations abolishing the function of CFTR, a protein whose role is chloride’s mobilization in the epithelial cells of various organs. Recently a therapy focused on small molecul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parodi, Alice, Righetti, Giada, Pesce, Emanuela, Salis, Annalisa, Tomati, Valeria, Pastorino, Cristina, Tasso, Bruno, Benvenuti, Mirko, Damonte, Gianluca, Pedemonte, Nicoletta, Cichero, Elena, Millo, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955485/ https://www.ncbi.nlm.nih.gov/pubmed/35337072 http://dx.doi.org/10.3390/ph15030274

Ejemplares similares

Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors
por: Righetti, Giada, et al.
Publicado: (2020)

CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium
por: Braccia, Clarissa, et al.
Publicado: (2022)

New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach
por: Righetti, Giada, et al.
Publicado: (2020)

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
por: Capurro, Valeria, et al.
Publicado: (2021)

Vx-809, a CFTR Corrector, Acts through a General Mechanism of Protein Folding and on the Inflammatory Process
por: Pecoraro, Michela, et al.
Publicado: (2023)

Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells
por: Stanton, Bruce A., et al.
Publicado: (2015)

Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators
por: Sabbadini, Roberto, et al.
Publicado: (2021)

Matrine in association with FD-2 stimulates F508del-cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809
por: Marengo, Barbara, et al.
Publicado: (2017)

Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR
por: Farinha, Carlos M, et al.
Publicado: (2015)

NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis
por: Brandas, Chiara, et al.
Publicado: (2021)

Correctors modify the bicarbonate permeability of F508del-CFTR
por: Fiore, Michele, et al.
Publicado: (2020)

Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors
por: Saint-Criq, Vinciane, et al.
Publicado: (2021)

Pharmacological Correctors of Mutant CFTR Mistrafficking
por: Pedemonte, Nicoletta, et al.
Publicado: (2012)

Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel
por: Pedemonte, Nicoletta, et al.
Publicado: (2020)

High-Content Surface and Total Expression siRNA Kinase Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance F508del-CFTR Rescue
por: Perkins, Lydia A., et al.
Publicado: (2018)

Functional Rescue of F508del-CFTR Using Small Molecule Correctors
por: Molinski, Steven, et al.
Publicado: (2012)

Constrained Bithiazoles: Small Molecule Correctors of Defective ΔF508–CFTR Protein Trafficking
por: Coffman, Keith C., et al.
Publicado: (2014)

Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain
por: Odolczyk, Norbert, et al.
Publicado: (2013)

Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators
por: Terlizzi, Vito, et al.
Publicado: (2023)

The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
por: Sondo, Elvira, et al.
Publicado: (2022)

Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity
por: Armirotti, Andrea, et al.
Publicado: (2019)

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
por: Amico, Giulia, et al.
Publicado: (2019)

Small molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states
por: Riepe, Celeste, et al.
Publicado: (2023)

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
por: Borgo, Christian, et al.
Publicado: (2022)

Targeting protein–protein interactions to rescue Δf508-cftr: a novel corrector approach to treat cystic fibrosis
por: Devesa, Isabel, et al.
Publicado: (2013)

Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
por: Matos, Ana M., et al.
Publicado: (2021)

Production of CFTR-ΔF508 Rabbits
por: Yang, Dongshan, et al.
Publicado: (2021)

Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing
por: Fossa, Paola, et al.
Publicado: (2022)

Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes
por: Baldassarri, Margherita, et al.
Publicado: (2022)

Recovery of ΔF508-CFTR Function by Citrate
por: Borkenhagen, Beatrice, et al.
Publicado: (2022)

Defective Fluid Secretion from Submucosal Glands of Nasal Turbinates from CFTR(-/-) and CFTR(ΔF508/ΔF508) Pigs
por: Cho, Hyung-Ju, et al.
Publicado: (2011)

Dual Activity of Aminoarylthiazoles on the Trafficking and Gating Defects of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Caused by Cystic Fibrosis Mutations
por: Pedemonte, Nicoletta, et al.
Publicado: (2011)

Characterization of Nasal Potential Difference in cftr Knockout and F508del-CFTR Mice
por: Saussereau, Emilie Lyne, et al.
Publicado: (2013)

Bithiazole Correctors Rescue CFTR Mutants by Two Different Mechanisms
por: Loo, Tip W., et al.
Publicado: (2013)

Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
por: Spanò, Virginia, et al.
Publicado: (2021)

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
por: Stefano, Daniela De, et al.
Publicado: (2014)

Benzbromarone Stabilizes ΔF508 CFTR at the Cell Surface
por: Loo, Tip W., et al.
Publicado: (2011)

In vivo model for modulators of CFTR(ΔF508) misfolding
Publicado: (2012)

VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
por: Ren, Hong Yu, et al.
Publicado: (2013)

Therapeutic Potential for CFTR Correctors in Autosomal Recessive Polycystic Kidney Disease
por: Yanda, Murali K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lkml3e9ua3tl1d8qmog9ku8rck